4th Pediatric Infectious Diseases Conference
 
 
Home  Back   ISSN 0973 - 0958
 
User name :
Password :
Follow Us : Follow On Facebook Follow On Twitter Follow On Youtube
FIND DIAGNOSIS
FIND DIAGNOSIS
Find Diagnosis
Pedi Poll
Today's Poll
Should teicoplannin, colistin be used in case of neonatal sepsis where culture does not reveal any organism_?
No, it should be used only after drug sensitivity report
Yes, under guidance of an infectious disease expert
SECOND GENERATION ANTI SEIZURE DRUGS
Second Generation Anti Seizure Drugs(SGASD)
New Derivatives Of First Line ASDs
New Derivatives Of First Line ASDs
Chandra Mohan Kumar
Postgraduate Department of Pediatrics, Narayana Medical College, Nellore, India.

Address for Correspondence:
Dr Chandra Mohan Kumar, Assistant Professor, PG Dept of Pediatrics, Narayana Medical College, Nellore, India- 524002. Email: cmkumar1@rediffmail.com

Continued...

New Derivatives or formulations of First line ASDs New Derivatives or Formulations of First Line ASDs

Zonisamide: It was recently approved in US for adjunctive treatment of partial seizures although it has been used in Japan for more than a decade now. Chemically it is a sulphonamide. It inhibits a particular voltage activated calcium channel known as T current. It also inhibits sodium channel. It is well absorbed and metabolized by acetylation and glucuronidation. Zonisamide extensively binds to erythrocytes, resulting in an eight-fold higher concentration of zonisamide in red blood cells (RBC) than in plasma. Zonisamide is easy to titrate and has a short latency of onset, thereby making it an attractive therapeutic alternative. It is excreted through kidneys. Its important adverse effect is development of renal calculi (19). But various studies in Japan have confirmed its efficacy and safety (20). It has been found efficacious in refractory partial epilepsy (21).

Table 2: Clinical Uses of Second Generation Anti-seizure drugs in Pediatric Practice Clinical Uses of Second Generation Anti Seizure Drugs


Drug
Acts on
Indications
Dose
NMDA & GABA
Adjunctive therapy for partial seizures with or without generalization. Adjunctive therapy for partial and generalized seizures associated with Lennox-Gastaut syndrome
Start with 15mg/mg/day and increase up to 45mg/kg/day or seizure control is achieved
GABA
Adjunctive treatment of partial seizures with or without generalization in patients older than 12 years
25-40 mg/kg/day and given in divided doses (three times a day).
Sodium Channel
Partial epilepsy, Add-on treatment of generalized seizures in Lennox-Gastaut syndrome, Childhood and Juvenile absence, Juvenile myoclonic epilepsy
Start with 0.3mg/kg/day. Increase 0.3 mg/kg weekly to up to 4.5-7 mg/kg/day or seizure control is achieved
Sodium Channel
Adjunctive therapy for partial and generalized seizures in adult and pediatric patients older than 2 years of age. Adjunctive therapy for Lennox-Gastaut syndrome and infantile spasms, Juvenile myoclonic epilepsy
Start with 1-3 mg/kg/day and increase 1-3 mg/kg weekly up to 5-9 mg/kg/day in two divided doses or seizure control is achieved
GAT1/GABA
Refractory partial epilepsy in children above 12 years of age
Start with 4 mg daily and increase 4 mg weekly to reach a maximum dose of 32 mg daily or seizure control is achieved
Not Known
Partial seizures with or without generalization. Adjunctive therapy for Juvenile myoclonic epilepsy
Start with 20 mg/kg in two divided doses and increase 20 mg/kg every 2 weekly up to 60 mg/kg/day or seizure control is achieved
GABA
Refractory partial seizures, Infantile spasms
40 mg/kg/day, increasing to 80 to 100 mg/kg/day or seizure control is achieved
Zonisamide
Ca2+ (T Current)
Adjunctive treatment of partial seizures in patients older than 16 years
Start with 100 mg/day and increase 100 mg every 2 weeks up to 400 mg/day or seizure control is achieved


 
 
Educational Section
 
Disclaimer:
The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
 
copyright ©2011 website design & development by Levioza
Follow Us
Follow us on :
Folllow Us